Novartis Looks To Extend Top-Selling Cosentyx Into Juvenile Arthritis

Novartis AG is busily extending the reach of its top-selling anti-inflammatory Cosentyx into pediatric indications and expects to make regulatory submissions “within weeks”, after obtaining positive results from the Phase III JUNIPERA study in two subtypes of juvenile idiopathic arthritis. 

Clinical findings from the JUNIPERA study of Cosentyx (secukinumab) in pediatric patients with juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) will be presented on 5 June at the European Congress of Rheumatology (EULAR), and regulatory submissions in Europe and US are anticipated in the coming weeks, Novartis said, while presenting top-line data on 2 June